ESLA vs. SABS, QNCX, OKYO, DYAI, ACHL, TARA, INKT, CYTH, SRZN, and INAB
Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include SAB Biotherapeutics (SABS), Quince Therapeutics (QNCX), OKYO Pharma (OKYO), Dyadic International (DYAI), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), Cyclo Therapeutics (CYTH), Surrozen (SRZN), and IN8bio (INAB). These companies are all part of the "biological products, except diagnostic" industry.
Estrella Immunopharma (NASDAQ:ESLA) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.
SAB Biotherapeutics received 17 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.
SAB Biotherapeutics has a consensus target price of $15.50, indicating a potential upside of 327.00%. Given SAB Biotherapeutics' higher probable upside, analysts clearly believe SAB Biotherapeutics is more favorable than Estrella Immunopharma.
Estrella Immunopharma has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,884.10%. SAB Biotherapeutics' return on equity of -144.66% beat Estrella Immunopharma's return on equity.
0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Estrella Immunopharma has higher earnings, but lower revenue than SAB Biotherapeutics.
Estrella Immunopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
In the previous week, Estrella Immunopharma had 1 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 1.89 beat Estrella Immunopharma's score of 1.38 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.
Summary
SAB Biotherapeutics beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.
Get Estrella Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Estrella Immunopharma Competitors List
Related Companies and Tools
